MARKET

SNSS

SNSS

Sunesis Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3943
-0.0256
-6.10%
Opening 12:50 11/14 EST
OPEN
0.4300
PREV CLOSE
0.4199
HIGH
0.4301
LOW
0.3500
VOLUME
1.87M
TURNOVER
--
52 WEEK HIGH
1.770
52 WEEK LOW
0.2000
MARKET CAP
43.89M
P/E (TTM)
-0.7499
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SNSS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SNSS News

  • Sunesis Pharmaceuticals, Inc. (SNSS) Management on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.1d ago
  • Sunesis Pharmaceuticals EPS beats by $0.03
  • seekingalpha.1d ago
  • Sunesis Pharmaceuticals Q3 EPS $(0.06) Beats $(0.08) Estimate
  • Benzinga.1d ago
  • Sunesis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Highlights
  • GlobeNewswire.1d ago

More

Industry

Biotechnology & Medical Research
-0.15%
Pharmaceuticals & Medical Research
-0.52%

Hot Stocks

Name
Price
%Change

About SNSS

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company’s lead programs are Vecabrutinib, SNS-510 and TAK-580. The Company also offers Vosaroxin, an anticancer quinolone derivative (AQD), which is used for the treatment of acute myeloid leukemia (AML). Vecabrutinib is a selective, reversible, non-covalent binding inhibitor of Bruton's tyrosine kinase (BTK) inhibitors. SNS-510 is a phosphoinositide dependent protein kinase 1 (PDK1) inhibitors. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors.
More

Webull offers Sunesis Pharmaceuticals, Inc. (SNSS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.